Please login to the form below

Not currently logged in
Email:
Password:

lorlatinib

This page shows the latest lorlatinib news and features for those working in and with pharma, biotech and healthcare.

Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial

Pfizer’s ALK inhibitor Lorbrena hits the mark in head-to-head lung cancer trial

Lorbrena (lorlatinib) reduced the risk of disease progression or death by 72% in ALK-positive NSCLC patients compared to Xalkori (crizotinib) in the phase 3 CROWN trial, presented over the weekend

Latest news

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Create Health

A healthcare marketing agency that shares your passion for making things better. Our clients with solve real health problems every...

Latest intelligence

Covid-19 redefines rules of customer engagement
Oli Hudson, Content Director at Wilmington Healthcare, explores how the pandemic has changed pharma’s relationship with HCPs...
Ongoing Virtual Communication between MSLs and Physicians: a Customer Story
Learn how one of our clients used the Impetus InSite Platform to connect their MSLs with regional groups of physicians....
The concordance conundrum: understanding the complexities of behaviour change
Understanding behaviour change looks at the six fundamental steps required to change human behaviour and discusses why HCPs need to start here if concordance is to be improved....

Infographics